Thursday, 30 July 2026
RACGP compliance risks in reforms, New data on miscarriage prevalence, Rural health training program overhaul
- 01
RACGP warns of compliance risks in proposed health insurance reforms
The RACGP expressed concerns over the proposed Health Insurance Amendment Act, which could impose fines on GP clinics falsely claiming participation in the bulk billing PIP. The college cannot endorse the use of AI in compliance checks without amendments, citing risks of automated decisions reminiscent of the 'Robodebt' scheme. RACGP president Dr Michael Wright emphasised the need for human oversight and transparent criteria to avoid burdensome compliance processes. The college also called for measures to ensure incentive payments keep pace with inflation and for a clear distinction between deliberate misconduct and administrative errors.
- 02
AIHW releases first national data on miscarriage prevalence
The Australian Institute of Health and Welfare (AIHW) has released its first official data on early pregnancy loss, revealing that 30% of women who gave birth in 2022 had previously experienced at least one miscarriage. The report indicates that approximately four in five pregnancy-loss-related hospitalisations are due to miscarriages, with 60% of these admissions occurring in women aged 30 to 39. The Early Pregnancy Loss Coalition (EPLC) described the data as a significant step in understanding early-term pregnancy loss and emphasised the need for further data collection to address existing gaps. The report also highlighted the psychological impact of miscarriage, which is often underestimated in clinical practice.
- 03
Federal government revamps $1.36bn rural health training program
The federal government has overhauled the Rural Health Multidisciplinary Training Program, shifting its focus from placement numbers to tracking graduates' long-term careers in rural areas. The revamped program will distribute $1.36 billion between 2026-27 and 2031-32 to support education and clinical training for various health students. Universities must now demonstrate that their training leads to improved recruitment and retention of health professionals in regional, rural, and remote communities. The reforms also emphasise First Nations health outcomes and require universities to align their activities with local workforce needs.
- 04
Staff Survey Reveals Low Morale in Digital Health Rollout
A staff survey has revealed significant discontent among employees of the Single Digital Patient Record Implementation Authority, with 92% of respondents indicating low morale. Only 39% would recommend the organisation as a great place to work, a decline from previous years. CEO Dr Teresa Anderson outlined various initiatives aimed at addressing staff concerns, but many employees view these efforts as largely symbolic. A psychosocial review of the workplace culture is expected to be released soon, which may lead to consequences for management.
- 05
ADHA to assume control of national healthcare provider directory by 2027
The Australian Digital Health Agency (ADHA) plans to take over the national Healthcare Provider Directory from Services Australia, aiming to enhance healthcare interoperability. This transition is set for February 2027 and is part of a broader initiative to consolidate provider information and facilitate FHIR-based information exchange. Currently, only four organisations have integrated individual provider identifiers into My Health Record uploads, with most exemptions expected to end in December 2026. The ADHA's report indicates that 35 of the 44 actions in the National Healthcare Interoperability Plan are complete, with a focus on implementation and sector engagement in the coming years.
- 06
Biogen reports strong quarterly earnings; AstraZeneca faces setbacks
Biogen reported $2.7 billion in revenue for the second quarter, a 3% increase from the previous year, driven by strong sales of its products, including a 15% rise in Leqembi sales for Alzheimer’s disease. AstraZeneca, while optimistic about reaching $80 billion in sales by 2030, faces challenges with delays in its breast cancer drug Etcamah and a recent trial failure for eplontersen, leading to a drop in share prices. GSK continues to build its oncology business, highlighting new drug prospects as key revenue drivers despite current earnings from this sector being relatively low. The earnings reports reflect varying levels of confidence and challenges within these major pharmaceutical companies.
via BioPharma Dive
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.